Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Assets (2016 - 2025)

Guided Therapeutics' Assets history spans 16 years, with the latest figure at $903000.0 for Q3 2025.

  • For Q3 2025, Assets fell 27.7% year-over-year to $903000.0; the TTM value through Sep 2025 reached $903000.0, down 27.7%, while the annual FY2024 figure was $1.4 million, 17.44% down from the prior year.
  • Assets for Q3 2025 was $903000.0 at Guided Therapeutics, down from $940000.0 in the prior quarter.
  • Across five years, Assets topped out at $3.9 million in Q3 2022 and bottomed at $903000.0 in Q3 2025.
  • The 5-year median for Assets is $1.7 million (2021), against an average of $1.9 million.
  • The largest annual shift saw Assets skyrocketed 548.9% in 2021 before it crashed 51.51% in 2023.
  • A 5-year view of Assets shows it stood at $2.0 million in 2021, then surged by 65.0% to $3.4 million in 2022, then tumbled by 50.42% to $1.7 million in 2023, then dropped by 17.44% to $1.4 million in 2024, then crashed by 34.47% to $903000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Assets are $903000.0 (Q3 2025), $940000.0 (Q2 2025), and $967000.0 (Q1 2025).